ArticleKidney international reports2026
Claims-Based Phenotyping of Acute Kidney Transplant Rejection in a National Medicare Cohort.
Article in Kidney international reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Introduction: National transplant registries record acute rejection (AR) without the granularity needed to study rejection heterogeneity and prognosis at scale. Whether AR can be stratified by type and severity in national claims data using a claims-based algorithm, and whether these phenotypes correlate with graft outcomes, remains unclear. Methods: We conducted a cohort study using the US Renal Data System (USRDS) data including adult kidney transplant recipients from 2012-2021. AR within 12 months posttransplant was identified using International Classification of Diseases codes for transplant complications with evidence of antirejection treatment within 2 weeks. Episodes were categorized by type and severity based on treatment regimen. Biopsy-associated AR was defined by renal biopsy within 14 days before the treatment. Death-censored graft survival was assessed using Kaplan-Meier methods and multivariable Cox proportional hazards models. Results: Among 92,845 recipients, 5712 AR episodes were identified (69.4% mild acute-cellular rejection [ACR], 8.8% severe ACR, 19.7% antibody-mediated rejection [AMR], and 2.1% mixed [ACR + AMR]). Among 3052 biopsy-confirmed episodes, 3-year death-censored graft survival differed meaningfully across phenotypes (87.9% mild ACR, 80.7% severe ACR, 73.5% AMR, and 68.4% mixed [ACR + AMR] [ Conclusion: Claims-based phenotyping can identify clinically meaningful AR subtypes and prognostic gradients at national scale, enabling more granular national rejection surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.